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Abstract
Aims: Coronary artery disease (CAD) and atrial fibrillation (AF) are major determinants of morbidity and 
mortality. A combined treatment with antiplatelet agents and vitamin K antagonists limits the risk of stent 
thrombosis and stroke while increasing the rate of bleeding. The objective of this study was to investigate the 
impact of atrial fibrillation (AF) on long-term clinical outcomes in patients with CAD undergoing percutane-
ous coronary intervention (PCI) with drug-eluting stents (DES).
Methods and results: Among 6,308 consecutive patients undergoing PCI with DES between 2002 and 2009, 
323 (5.3%) patients were diagnosed with AF. We compared clinical outcomes between patients with and those 
without AF throughout four years. The primary endpoint was a composite of all-cause mortality, myocardial infarc-
tion (MI), ischaemic stroke, and BARC bleeding type 3b/3c/5a/5b. In adjusted analyses, the primary composite 
endpoint was more frequent among patients with AF (HR 1.59, 95% CI 1.26-2.00; p<0.001). Differences were 
driven by an increased risk of all-cause mortality (HR 1.67, 95% CI 1.27-2.20; p=0.003), ischaemic stroke (HR 
3.09, 95% CI 1.45-6.56; p=0.003), and intracranial bleeding (HR 4.28, 95% CI 1.36-13.48; p=0.013). We observed 
a gradient of risk among patients with higher CHA2DS2-VASc scores and modified outpatient bleeding risk index.
Conclusions: Among patients with CAD undergoing revascularisation with DES, AF confers an increased 
risk of all-cause mortality, ischaemic stroke, and intracranial bleeding. The hazard imposed by AF correlates 
with the CHA2DS2-VASc score.
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Introduction
Coronary artery disease (CAD) remains the leading cause of mor-
tality in industrialised countries, while atrial fibrillation (AF) is a 
major risk factor for cerebrovascular accidents1 and is associated 
with a two to threefold increased risk of stroke among patients with 
CAD or heart failure1. CAD and AF coexist in up to 25% of patients 
with stable CAD or acute myocardial infarction (MI)2-7, which may 
be related to common risk factors including advanced age, diabetes, 
hypertension, and congestive heart failure8,9. Apart from cerebro-
vascular events, AF has been associated with a one-and-a-half to 
twofold increased risk of mortality in the general population after 
adjustment for pre-existing cardiovascular conditions8 as well as 
adverse in-hospital and long-term outcome after MI4,10.
Effective treatments of both AF and CAD have major prognostic 
implications for event-free survival in contemporary clinical prac-
tice. Vitamin K antagonists (VKA) reduce the risk of cerebrovascu-
lar events among patients with AF11. Similarly, percutaneous 
coronary interventions (PCI) reduce the risk of death and MI among 
patients with acute coronary syndromes while improving symp-
toms and quality of life among patients with stable CAD12. Dual 
antiplatelet therapy (DAPT) minimises the risk of stent thrombosis 
(ST) following implantation of stents and has become a mainstay in 
contemporary PCI practice. While the combination of antiplatelet 
agents with VKA aims to prevent thromboembolic events related to 
AF as well as ST, this therapeutic strategy imposes an increased risk 
of bleeding and malcompliance13. European and North American 
consensus documents provide a comprehensive review of clinical 
data investigating the delicate balance between stroke prevention, 
stent thrombosis and bleeding among patients with AF undergoing 
PCI. Since prospective clinical data are, however, limited, consen-
sus documents are based substantially upon expert opinion and 
emphasise the need for further investigation14-16. Although drug-
eluting stents (DES) have considerably reduced the risk of repeat 
revascularisation compared with bare metal stents, this benefit 
comes at the expense of a prolonged duration of DAPT and triple 
antithrombotic therapy in case of concomitant AF17. Despite the 
introduction of bleeding risk scores18, the balance between the risk 
of stroke on the one hand and haemorrhagic events on the other is 
based largely on clinical judgement, and little is known regarding 
the impact of AF on ischaemic and haemorrhagic outcomes among 
patients undergoing PCI with DES. The objective of the present 
analysis was therefore to assess the impact of AF among patients 
with CAD undergoing PCI with the unrestricted use of DES in rou-
tine clinical practice during long-term clinical follow-up through 
four years.
Methods
PATIENT POPULATION
All patients undergoing implantation of DES at Bern University 
Hospital, Switzerland, were prospectively entered into a dedicated 
database. Between April 2002 and March 2009, a total of 6,535 
consecutive patients underwent PCI with the unrestricted use of 
early and newer-generation DES. Drug-eluting stents were used in 
more than 90% during the study period. Considering the registry 
character of the study, no formal exclusion criteria applied. Demo-
graphic and clinical characteristics, information on PCI, and hospi-
tal outcome data were systematically collected. The study was 
approved by the institutional ethics committee at Bern University 
Hospital, Switzerland, and complied with the Declaration of Hel-
sinki. Written informed consent for prospective follow-up was 
obtained from all patients.
PROCEDURES
It was generally recommended that oral anticoagulation be discon-
tinued in patients undergoing elective coronary angiography three 
days prior to intervention with an intended target INR <2 at the time 
of the procedure. In patients with acute coronary syndromes, percu-
taneous coronary intervention was performed without prior discon-
tinuation of oral anticoagulation. Patients were loaded with a 
thienopyridine, and anticoagulation during the intervention was 
guided by measurement of activated clotting time (ACT). A radial 
access was chosen if the bleeding risk appeared excessive due to 
elevated INR values. Unfractionated heparin in a dose of 5,000 IU 
or 70-100 IU/kg was administered during the procedure to maintain 
an ACT >250 seconds. PCI was performed in accordance with cur-
rent guidelines. The antiplatelet and antithrombotic regimen was 
installed upon the discretion of the operator. A 12-lead electrocar-
diogram was routinely obtained before and after the procedure and 
cardiac enzymes were assessed within 24 hours of the procedure. 
Creatinin kinase (CK), CK-MB and troponin T were repeated every 
six to eight hours until identification of the peak levels in patients 
with signs of ischaemia.
DATA COLLECTION
AF was not formally classified at baseline. All medical records of 
patients with AF at baseline were therefore evaluated by three 
investigators (TP, TZ, CP), including a systematic review of all 
electrocardiograms at the time of admission, during the hospitalisa-
tion and at discharge. Reasons for VKA other than AF (mechanic 
valve prosthesis, pulmonary embolism, venous thromboembolism, 
pulmonary hypertension [>50 mmHg], left ventricular ejection 
fraction <30%, left ventricular aneurysm or thrombus) were also 
recorded. All patients were actively followed up to ascertain major 
adverse cerebrovascular and cardiovascular events. Survival data 
for all patients were obtained from hospital records and municipal 
civil registries. A health questionnaire was sent to all living patients 
with questions on rehospitalisation and major adverse cardiac 
events19. In case of missing response, patients were contacted by 
telephone. General practitioners, referring cardiologists and patients 
were contacted as necessary for additional information. For patients 
who underwent treatment for major adverse cardiac events at other 
medical institutions, external medical records, discharge letters and 
coronary angiography documentation were systematically collected 
and reviewed. All major adverse cardiac events and bleeding events 
were adjudicated by a cardiologist, and all neurologic events by 
a neurologist. 
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DEFINITIONS
AF was defined as at least one ECG documented episode of irregu-
larly irregular RR intervals consistent with AF any time before dis-
charge. Patients with atrial flutter were also included in the analysis. 
CHADS2 scores and CHA2DS2-VASc scores were created for 
patients with AF by the addition of points assigned to individual 
risk factors for stroke. Congestive heart failure, history of hyperten-
sion, age ≥75 years, and diabetes contributed one point each to the 
CHADS2 score, whereas two points were added for previous cere-
brovascular events20. The CHA2DS2-VASc score assigned one point 
each for congestive heart failure, hypertension, age 65-74 years, 
diabetes, vascular disease, and female gender, and two points for 
age ≥75 years and a history of previous cerebrovascular events, 
respectively21. 
Bleeding risk was assessed using the modified Outpatients 
Bleeding Risk Index (mOBRI) which takes into account age 
≥65 years, a history of stroke, a history of gastrointestinal bleed-
ing, recent myocardial infarction, anaemia, renal insufficiency, 
and diabetes. Patients with none of the factors are assumed to 
have a low risk of bleeding, patients with one to two factors have 
an intermediate risk of bleeding, and patients with three to four 
factors are expected to have a high risk of bleeding22,23. We pre-
specified a composite primary endpoint consisting of all-cause 
mortality, non-fatal MI, ischaemic stroke, and BARC (Bleeding 
Academic Research Consortium) bleeding type 3b, 3c, and type 
5a and 5b. Cardiac death was classified as death secondary to an 
immediate cardiac cause, procedure-related mortality, and death 
of unknown cause. MI was classified as Q-wave or non-Q-wave 
MI. Q-wave myocardial infarction was diagnosed in the circum-
stance of symptoms or signs of ischaemia in the presence of new 
pathological Q-waves in ≥2 contiguous leads. Non-Q-wave myo-
cardial infarction was defined as an elevation in CK to ≥2x upper 
limit of normal (ULN) and a rise in CK-MB or troponin to ≥3x 
ULN in the presence of ischaemic symptoms or ischaemic ECG 
changes. Target vessel revascularisation (TVR) was defined as 
any repeat revascularisation within the vessel of the target lesion. 
Target lesion revascularisation (TLR) required revascularisation 
of a stenosis within the stent or the 5-mm borders adjacent to the 
stent. Stent thrombosis (ST) was defined according to the 
Academic Research Consortium (ARC) definitions24. Bleeding 
was classified in accordance with the definition by the BARC, as 
well as the TIMI and the GUSTO definition25. Since the BARC 
definition was only recently published, we refrained from report-
ing BARC bleeding types 1 and 2 due to difficulties in categoris-
ing objectively such events in a retrospective fashion. BARC 
bleeding type 3a was defined as an overt bleeding event plus 
a drop in haemoglobin of 3 to 5 g/dl or any transfusion in the 
setting of overt bleeding; type 3b was defined as overt bleeding 
plus haemoglobin drop ≥5 g/dl, cardiac tamponade, bleeding 
requiring surgical intervention for control, and bleeding requiring 
intravenous vasoactive agents; type 3c was documented in the 
presence of intracranial haemorrhage or intraocular bleeding. 
BARC bleeding type 4 compromised perioperative intracranial 
bleeding, reoperation after closure of sternotomy for the purpose 
of controlling bleeding, and transfusion of ≥5 units packed red 
blood cells within 48 hours, and was adjudicated by a cardiovas-
cular surgeon (TC). Type 5a and type 5b were determined as prob-
able and definite fatal bleeding, respectively. All cerebrovascular 
events were reviewed and adjudicated by two board certified neu-
rologists (SJ, HM) and classified as ischaemic stroke, intracranial 
haemorrhage, transient ischaemic attack and unclear cerebrovas-
cular events. Ischaemic stroke was diagnosed in case of a focal 
neurological deficit (motor or sensory deficit, dysarthria, aphasia, 
visual loss) with duration of ≥24 hours and/or imaging documen-
tation of ischaemia and exclusion of intracranial bleeding. 
Transient ischaemic attack was defined as a neurological deficit 
with resolution of symptoms within 24 hours and without evi-
dence of ischaemic brain injury from neuroimaging. An unclear 
neurologic event comprised all events reported by the patients 
without appropriate documentation to allow further classification 
into ischaemic stroke or transient ischaemic attack. In case of 
multiple events in one patient, only the first event in each event 
category was used for the purpose of this analysis. 
STATISTICAL ANALYSIS
The baseline clinical and procedural characteristics and the 
medications at discharge were presented as counts and percent-
ages (%) for categorical variables and as mean and standard 
deviation (SD) for continuous variables. Differences between 
the two groups (AF and absence of AF) were performed using 
chi-square test for categorical variables and Student’s t-test for 
continuous variables. Incidence rates (IR) per 100 patient years 
(PY) were reported rather than crude event rates to account for 
potential differences in follow-up time. We performed Cox pro-
portional hazard models, with initial adjustment for type of stent 
and full adjustment in a multivariable analysis for age, gender, 
hypertension, hyperlipidaemia, diabetes, smoking, renal impair-
ment, LVEF and ACS to compare the clinical outcomes between 
patients with and without AF at baseline. Hazard ratios and 
Kaplan-Meier curves with 95% confidence intervals were con-
structed for the time from index PCI until the end of four years. 
We further categorised the AF group according to onset (pre-
existing AF vs. new onset periprocedurally), baseline risk 
according to CHA2DS2-VASc score, type of AF (permanent, per-
sistent or paroxysmal), and compared the clinical outcomes of 
these groups, separately, to those presenting with no AF at base-
line. Then, we performed landmark analyses according to a pre-
specified landmark point at one year (360 days) or six months 
(180 days) and estimated hazard ratios and cumulative IRs sepa-
rately for events up to one year/six months, and from after one 
year/six months until the end of follow-up at four years. Strati-
fied analyses were performed by prespecified baseline charac-
teristics and χ2 test was used to assess the interaction between 
presence or absence of AF and these characteristics. Statistical 
analyses were performed using STATA release 11.2 (Stata Corp., 
College Station, TX, USA). All p-values are two-sided.
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Results
Among 6,308 patients undergoing PCI with at least one DES 
between April 2002 and March 2009, 87 patients were excluded 
since they were not followed up after index PCI, and 180 patients 
were excluded due to indications for oral anticoagulation other than 
AF. Therefore, 6,041 patients were included in the analysis.
AF was documented in 323 patients (5.3%). Two patients had 
undergone radiofrequency ablation prior to inclusion into the regis-
try and one patient had undergone left atrial appendage occlusion 
prior to inclusion. Among patients with AF, 26 patients (8.0%) had 
an INR >2 at the time of PCI, and a radial access was chosen in 
a single patient only, due to chronic occlusion of the iliac arteries 
bilaterally. Baseline characteristics of all patients undergoing PCI 
with or without AF are summarised in Table 1. Patients with AF 
were older (72±9 years vs. 63±12 years, p<0.001), had a higher 
prevalence of hypertension (66% vs. 57%, p=0.002), renal failure 
(5% vs. 3%, p=0.03), and reduced left ventricular ejection fraction 
(50±13% vs. 54±12%, p<0.001). Conversely, the prevalence of 
dyslipidaemia (48% vs. 53%, p=0.03), smoking (43% versus 52%, 
p=0.001) and a family history of CAD (22% vs. 28%, p=0.01) was 
lower in patients with AF. Procedural characteristics and medica-
tions at the time of discharge are shown in Table 2 and Table 3. 
Periprocedural administration of glycoprotein IIb/IIIa inhibitors 
was less frequent among patients with AF as compared to those 
without (17% vs. 23%, p=0.02). A CHADS2 score ≥2 was recorded 
Table 1. Baseline characteristics.
Overall
Absence of atrial 
fibrillation
Atrial fibrillation p
Total (n) 6,041 5,718 323 -
Age yr (SD) 63.9 (11.7) 63.4 (11.6) 71.9 (8.9) <0.001
Sex, male, n (%) 4,555 (75.4) 4,318 (75.5) 237 (73.4) 0.39
BMI mean kg/m2 (SD) 27.3 (4.3) 27.3 (4.3) 27.3 (4.7) 0.90
Cardiovascular risk factors
Hypertension, n (%) 3,477 (57.6) 3,264 (57.1) 213 (65.9) 0.002
Dyslipidaemia, n (%) 3,229 (53.5) 3,075 (53.8) 154 (47.7) 0.033
Diabetes mellitus, n (%) 1,069 (17.7) 1,000 (17.5) 69 (21.4) 0.08
Smoking at baseline, n (%) 3,105 (51.4) 2,967 (51.9) 138 (42.7) 0.001
Anaemia at baseline, n (%) 1,278 (21.2) 83 (25.7) 1,195 (20.9) 0.040
Family history of CAD, n (%) 1,694 (28) 1,623 (28.4) 71 (22) 0.013
Clinical features
Renal failure (creatinine ≥200 μmol/l), n (%) 166 (2.7) 151 (2.6) 15 (4.6) 0.032
Congestive heart failure – – 137 (42.4) –
Prior stroke or TIA – – 35 (10.8) –
LV ejection fraction mean (SD) 54.1 (11.9) 54.3 (11.8) 50.3 (12.9) <0.001
LV ejection fraction <50%, n (%) 127 (2.1) 116 (2) 11 (3.4) 0.09
Acute coronary syndrome, n (%) 3,294 (54.5) 3,138 (54.9) 156 (48.3) 0.021
UA/Non-ST-elevation MI 1,726 (52.4) 1,643 (52.4) 83 (53.2) 0.84
ST-elevation MI 1,566 (47.6) 1,493 (47.6) 73 (46.8) –
Anaemia assessed using WHO criteria
among 203 AF patients (62%). 315 patients (98%) were discharged 
on aspirin and 321 patients (99%) on clopidogrel, and 62 patients 
(19.2%) were discharged on oral anticoagulation; in addition, 69 
patients (21%) were recommended to reinstall VKA within three 
months after the procedure. Amiodarone and digoxin were pre-
scribed to 56 (17.3%) and 22 (5.6%) patients with AF, respectively. 
At the end of follow-up, 40.5% and 3.8% of the patients with and 
without AF were on oral anticoagulation (p<0.001), respectively. 
Adherence to aspirin amounted to 90.7% among patients with AF, 
and to 67.4% among patients without AF p<0.0001); no difference 
with regard to clopidogrel intake was observed at the end of follow-
up (22.4% without AF vs. 20.5% with AF, p=0.50).
CLINICAL OUTCOME
Among patients with AF, 19 patients underwent radiofrequency 
ablation and two patients underwent percutaneous left atrial 
appendage occlusion during the study period. Patients with AF 
had a higher risk of the primary composite endpoint after initial 
(HR 2.08, 95% CI 1.66-2.61, p<0.0001) and full adjustment (HR 
1.59, 95% CI 1.26-2.00, p<0.0001) throughout four years of fol-
low-up with a similar hazard during the first (HR 1.67, 95% CI 
1.20-2.32, p=0.003) and subsequent years (HR 1.68, 95% CI 
1.19-2.37, p=0.003) (Table 4, Figure 1). Patients with new-onset 
AF were observed to have a higher risk of adverse outcome as 
compared to patients without AF (HR 2.04, 95% CI 1.38-3.00, 
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Months after index PCI
Adj HR (95% CI):1.59 (1.26-2.00); p<0.0001
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Months after index PCI
Adj HR (95% CI):1.52 (1.11-209); p=0.010
Adj HR (95% CI):1.66 (1.19-2.34); p=0.003
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Number at risk
AF 323 285 279 265 229 191 143 98 72
No AF 5,718 5,379 5,296 5,134 4,615 3,810 2,913 2,130 1,590
Figure 1. Primary composite outcome of all-cause mortality, 
myocardial infarction, stroke, and BARC bleeding type 3b, 3c, 5a, 
and 5b through 4 years of follow-up and landmark analysis with the 
landmark set at 1 year. The red line indicates patients with and the 
blue line patients without atrial fibrillation at baseline.
Months after index PCI
Adj HR (95% CI):
Pre-existing AF vs. No AF: 1.43(0.98-2.07); p=0.062
New-onset AF vs. No AF: 2.04(1.33-3.01); p<0.0001
New-onset AF vs. Pre-existing AF: 1.94 (1.01-3.71); p=0.048
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Number at risk
New-onset AF 129 117 116 110 98 78 52 39 25
Pre-existing AF 194 185 180 173 147 124 98 66 53
No AF 5,718 5,532 5,469 5,324 4,817 4,000 3,082 2,261 1,694
Figure 2. Primary composite outcome of all-cause mortality, 
myocardial infarction, stroke, and BARC bleeding type 3b, 3c, 5a, 
and 5b through four years of follow-up according to pre-existing 
atrial fibrillation or new onset of atrial fibrillation. The black line 
represents patients with new-onset atrial fibrillation during the 
course of the index hospitalisation. The red line represents patients 
with pre-existing atrial fibrillation prior to hospital admission. The 
blue line indicates patients without atrial fibrillation.
p<0.0001), and a strong trend towards adverse outcome was noted 
among patients with pre-existing AF (HR 1.43, 95% CI 0.99-2.08, 
p=0.06) (Figure 2).
Patients with AF had a higher risk of all-cause death after initial 
(HR 2.43, 95% CI 1.85-3.19, p<0.001), and full adjustment (HR 
1.67, 95% CI 1.27-2.20, p<0.003) (Table 4, Figure 3) up to four 
years. In a landmark analysis with cut-off set at one year, the risk of 
all-cause mortality increased steadily during the first (HR 1.51, 
95% CI 1.01-2.27, p=0.047) and subsequent years (HR 1.85, 95% 
CI 1.27-2.69, p=0.001). AF was associated with an increased risk 
of ischaemic stroke (HR 3.08, 95% CI 1.45-6.56, p=0.003) and 
intracranial bleeding (HR 4.28, 95% CI 1.36-13.48, p=0.013) after 
initial and full adjustment (Table 4). There was no difference 
between patients with and without AF in terms of ARC-defined ST 
(Table 5).
A graduated increase in the incidence rate (IR) of the primary end-
point was observed with increasing CHA2DS2-VASc scores (adjusted 
p for trend <0.0001) (Figure 4). At the same time, the risk of adverse 
clinical outcome tended to increase with increasing mOBRI score 
(Table 6).
A stratified analysis of the primary composite endpoint across 
major subgroups showed a fourfold increased risk among patients 
Months after index PCI
Adj HR (95% CI): 1.67 (1.27-2.20); p=0.000325
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Months after index PCI
Adj HR (95% CI): 1.51 (1.01-2.27); p=0.047
Adj HR (95% CI): 1.85 (1.27-2.69); p=0.001
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Number at risk
AF 323 302 296 283 245 202 150 105 78
No AF 5,718 5,332 5,469 5,324 4,817 4,000 3,082 2,261 1,694
Figure 3. All-cause mortality up to four years of follow-up and 
landmark analysis at one year. The red line indicates patients with 
and the blue line patients without atrial fibrillation at baseline.
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Table 3. Discharge medications.
Overall
Absence of atrial 
fibrillation
Atrial fibrillation p
Total (n) 6,041 5,718 323
Aspirin, n (%) 5,916 (97.9) 5,601 (97.9) 315 (97.5) 0.55
Clopidogrel, n (%) 5,961 (98.7) 5,640 (98.6) 321 (99.4) 0.45
Oral anticoagulation, n (%) 62 (1.0) 0 62 (19.2) <0.001
Beta-blocker, n (%) 3,724 (61.9) 3,524 (61.8) 200 (62.3) 0.87
ACE inhibitor, n (%) 3,150 (52.3) 2,964 (52) 186 (57.9) 0.038
AT II inhibitor, n (%) 878 (14.6) 829 (14.5) 49 (15.3) 0.72
Calcium antagonist, n (%) 616 (10.2) 573 (10.1) 43 (13.4) 0.055
Statin, n (%) 5,075 (84.3) 4,833 (84.8) 242 (75.4) <0.001
Oral antidiabetic, n (%) 650 (10.8) 608 (10.7) 42 (13.1) 0.18
Insulin, n (%) 319 (5.3) 295 (5.2) 24 (7.5) 0.07
Diuretics, n (%) 1,023 (17) 885 (15.5) 138 (43) <0.001
Proton pump inhibitor, n (%) 1,155 (19.2) 1,074 (18.8) 81 (25.2) 0.005
GP IIa/IIIb 1,362 (22.5) 1,306 (22.8) 56 (17.3) 0.021
Table 2. Procedural characteristics.
Overall
Absence of atrial 
fibrillation
Atrial fibrillation p
Total (n) 6,041 5,718 323
Type of stent 0.84
Early-generation DES* 3,941 (65.2) 3,732 (65.3) 209 (64.7)
Newer-generation DES¶ 2,100 (34.8) 1,986 (34.7) 114 (35.3)
Multivessel treatment, n (%) 1,161 (19.3) 1,104 (19.3) 57 (17.7) 0.47
No of vessels treated per patient, n (SD) 1.2 (0.4) 1.2 (0.4) 1.2 (0.4) 0.71
No of lesions treated per patient, n (SD) 1.6 (0.8) 1.6 (0.8) 1.6 (0.8) 0.82
Target vessel
Number of stents implanted, n (SD) 1.8 (1) 1.8 (1) 1.8 (1) 0.92
Average stent diameter, mm (SD) 2.9 (0.5) 2.9 (0.5) 2.8 (0.4) 0.016
Total stent length, mm (SD) 30.3 (18.5) 30.2 (18.4) 31.3 (19.8) 0.28
Left main, n (%) 168 (2.8) 158 (2.8) 10 (3.1) 0.72
Left anterior descending, n (%) 2,973 (49.3) 2,816 (49.4) 157 (48.8) 0.83
Left circumflex, n (%) 1,573 (26.1) 1,504 (26.4) 69 (21.4) 0.05
Right coronary artery, n (%) 2,148 (35.6) 2,025 (35.5) 123 (38.2) 0.32
Arterial bypass graft, n (%) 14 (0.2) 14 (0.2) 0 (0) 0.37
Saphenous vein graft, n (%) 161 (2.7) 147 (2.6) 14 (4.3) 0.055
Length of hospital stay after PCI¶¶ 
(median, 25th to 75th percentile) 1 (1 to 2) 1 (1 to 2) 1 (1 to 4) <0.001
*Early-generation DES: sirolimus-eluting stent (Cypher), paclitaxel-eluting stent (TAXUS); ¶Newer-generation DES: everolimus-eluting stent (XIENCE V, 
Promus), zotarolimus-eluting stent (Endeavor, Resolute), biolimus-eluting stent (Biomatrix); ¶¶Duration of hospital stay in referring hospital not included
with AF and renal failure (HR 3.80, 95% CI 1.84-7.85), while 
patients with AF but without renal failure showed only a 47% increase 
in relative risk (HR 1.47, 95% CI 1.14-1.88). The difference was 
marginally significant (pinteraction=0.05) (Figure 5). Outcome among 
patients with AF treated with or without oral anticoagulation in 
addition to dual antiplatelet therapy is summarised in Figure 6. 
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Table 4. Clinical outcome.
Atrial 
fibrillation
Absence of 
atrial fibrillation
Initial adj HR 
(95% CI)
crude-p Full adj HR 
(95% CI)
Adj-p
323 5,718
Death n (%) 59 (22.5) 458 (9.6) 2.43 (1.85-3.19) <0.0001 1.67 (1.27-2.20) 0.0003
Cardiac events
Cardiac death, n (%) 31 (11.8) 233 (4.7) 2.47 (1.70-3.60) <0.0001 1.84 (1.26-2.71) 0.002
Myocardial infarction (MI), n (%) 16 (6.5) 223 (4.8) 1.36 (0.82-2.25) 0.24 1.37 (0.81-2.30) 0.24
Q-wave MI, n (%) 7 (2.7) 91 (2.0) 1.45 (0.67-3.13) 0.34 1.66 (0.75-3.66) 0.21
Non-Q-wave MI, n (%) 9 (3.7) 122 (2.7) 1.39 (0.71-2.73) 0.34 1.30 (0.65-2.59) 0.46
Target lesion revascularisation 25 (10.3) 473 (9.4) 0.99 (0.66-1.48) 0.97 1.07 (0.71-1.60) 0.76
Target vessel revascularisation 39 (16.3) 740 (14.8) 0.99 (0.72-1.36) 0.94 1.07 (0.77-1.48) 0.69
Death/MI 73 (27.6) 649 (13.6) 2.15 (1.69-2.73) <0.0001 1.62 (1.27-2.08) 0.0001
Cardiac death/MI 46 (17.7) 431 (8.9) 2.02 (1.49-2.73) <0.0001 1.69 (1.24-2.31) 0.001
Neurologic events
Ischaemic stroke 9 (3.4) 38 (0.8) 4.47 (2.16-9.24) <0.0001 3.08 (1.45-6.56) 0.003
TIA 2 (0.6) 21 (0.4) 1.79 (0.42-7.63) 0.43 1.16 (0.27-5.08) 0.84
Unclear neurologic event 2 (0.9) 7 (0.2) 5.47 (1.14-26.36) 0.034 3.04 (0.58-15.95) 0.19
Bleeding events
BARC bleeding-3a 10 (3.3) 81 (1.5) 2.22 (1.15-4.28) 0.017 1.79 (0.91-3.51) 0.09
BARC bleeding-3b 5 (1.6) 83 (1.5) 1.08 (0.44-2.67) 0.86 0.85 (0.34-2.11) 0.72
BARC bleeding-3c 4 (1.9) 17 (0.4) 4.50 (1.51-13.38) 0.007 4.28 (1.36-13.48) 0.013
BARC bleeding-4 1 (0.3) 8 (0.2) 2.41 (0.30-19.24) 0.41 2.98 (0.34-26.08) 0.32
BARC bleeding-5a 0 (0) 1 (0.02) 5.89 (0.24-144.3) 1.00
BARC bleeding-5b 1 (0.3) 4 (0.1) 4.37 (0.49-39.2) 0.19
TIMI major bleeding 10 (3.7) 92 (1.7) 1.98 (1.03-3.81) 0.040 1.59 (0.81-3.09) 0.18
TIMI minor bleeding 10 (3.3) 89 (1.6) 2.03 (1.05-3.90) 0.034 1.68 (0.86-3.29) 0.13
GUSTO severe bleeding 9 (3.4) 69 (1.4) 2.40 (1.20-4.80) 0.014 1.87 (0.92-3.81) 0.086
GUSTO moderate bleeding 6 (2.0) 58 (1.0) 1.85 (0.80-4.29) 0.15 1.25 (0.53-2.92) 0.61
Composite outcomes
Death/MI/ischaemic stroke 79 (31.0) 685 (14.7) 2.21 (1.75-2.80) <0.0001 1.67 (1.32-2.12) <0.0001
Cardiac death/MI/ischaemic stroke 54 (22.0) 471 (10.1) 2.18 (1.65-2.89) <0.0001 1.79 (1.32-2.12) <0.0001
Death/MI/ischaemic stroke/BARC 
bleeding 3b/3c/5a/5b 83 (34.0) 762 (16.4) 2.08 (1.66-2.61) <0.0001 1.59 (1.26-2.00) <0.0001
Adjusted for age, gender, hypertension, hyperlipidaemia, diabetes, smoking, renal impairment, LVEF, ACS, anaemia; Hazard ratios were calculated using 
Cox proportional hazard model. For comparisons with one group having no events, relative risk was calculated instead of hazard ratios using continuity 
correction and corresponding p values were obtained from Fisher’s test. 
Table 5. Stent thrombosis.
Atrial 
fibrillation
Absence of 
atrial fibrillation
Initial adj HR 
(95% CI)
crude-p Full adj HR 
(95% CI)
Adj-p
323 5,718
Definite ST
Early (0 to 30 days) 2 (0.6) 54 (1.0) 0.66 (0.16-2.71) 0.57 0.68 (0.16-2.86) 0.60
Late (31 to 360 days) 1 (0.3) 14 (0.3) 1.30 (0.17-9.92) 0.80 1.14 (0.14-8.99) 0.90
Very late (361 to 1,440 days) 1 (0.5) 61 (1.5) 0.32 (0.04-2.29) 0.26 0.40 (0.05-2.94) 0.37
Overall (0 to 1,440 days) 4 (1.5) 129 (2.7) 0.58 (0.21-1.56) 0.28 0.64 (0.24-1.76) 0.39
Definite or probable ST
Early (0 to 30 days) 17 (5.3) 177 (3.1) 1.73 (1.05-2.84) 0.031 1.62 (0.97-2.70) 0.064
Late (31 to 360 days) 2 (0.7) 30 (0.5) 1.22 (0.29-5.10) 0.79 1.08 (0.25-4.61) 0.92
Very late (361 to 1,440 days) 2 (0.9) 115 (2.9) 0.34 (0.08-1.37) 0.13 0.37 (0.09-1.50) 0.16
Overall (0 to 1,440 days) 21 (6.8) 322 (6.5) 1.21 (0.78-1.88) 0.39 1.17 (0.75-1.84) 0.49
Adjusted for age, gender, hypertension, hyperlipidaemia, diabetes, smoking, renal impairment, LVEF, ACS, anaemia.
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Table 6. Primary outcome.
n (CIR)
Crude HR (95% 
CI)
crude-p Adj HR (95% 
CI)
Adj-p
Absence of atrial fibrillation 762 (16.4) Reference Reference 
Atrial fibrillation
Low risk (mOBRI = 0) 2 (6.9) 0.77 (0.19-3.09) 0.72 1.34 (0.33-5.43) 0.68
Intermediate risk (mOBRI = 1-2) 74 (3.4) 2.04 (1.59-2.62) <0.001 1.53 (1.18-1.97) 0.001
High risk (mOBRI >2) 7 (18.4) 3.36 (1.51-7.51) 0.003 1.83 (0.81-4.13) 0.14
Adjusted for age, gender, hypertension, hyperlipidaemia, diabetes, smoking, renal impairment, LVEF, ACS, anaemia. mOBRI: Outpatients Bleeding Risk Index
Stratified analysis AF, n/N(IR) No AF, n/N(IR) HR (95% CI) p pinteract.
Primary outcome 83 762 1.59 (1.26-2.01) <0.001
Age 0.58
<65 years 12/68 (23.2) 299/3,003 (12.2) 1.95 (1.09-3.48) 0.024
≥65 71/255 (36.6) 463/2,715 (21.1) 1.69 (1.32-2.17) <0.001
Gender 0.47
Women 26/86 (39.4) 197/1,400 (16.9) 1.86 (1.22-2,83) 0.004
Men 57/237 (31.8) 565/4,318 (16.2) 1.48 (1.12-1.96) 0.006
Diabetes mellitus (n[%]) 0.72
No 63/254 (31.1) 578/4,718 (14.8) 1.61 (1.23-2.10) <0.001
Yes 20/69 (42.0) 184/1,000 (23.7) 1.41 (0.88-2.27) 0.153
Renal failure (creatinine) (n[%]) 0.05
No 71/308 (31.1) 703/5,567 (15.6) 1.47 (1.14-1.88) 0.003
Yes 12/15 (80.0) 59/151 (43.8) 3.62 (1.75-7.51) <0.001
Acute coronary syndrome (n[%]) 0.66
No 41/167 (31.6) 315/2,580 (15.4) 1.58 (1.13-2.21) 0.007
Yes 42/156 (36.9) 447/3,138 (17.2) 1.59 (1.15-2.20) 0.005
Adjusted for hypertension, hyperlipidaemia, smoking, LVEF and anaemia
.0     1                   2                          5
Figure 5. Stratified analysis of the primary composite outcome across major subgroups.
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Figure 6. Stratified analysis according to atrial fibrillation treated 
with or without oral anticoagulation at discharge: single components 
of the primary outcome in patients with no atrial fibrillation (blue 
bars), patients with atrial fibrillation on dual antiplatelet therapy 
without oral anticoagulation (red bars), and patients with atrial 
fibrillation on triple antithrombotic therapy (green bars).
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Figure 4. Primary outcome up to four years of follow-up according 
to severity of atrial fibrillation based on CHA2DS2-VASc score at 
baseline. The black line shows the Kaplan-Meier curve for patients 
with a CHA2DS2-VASc score >5. The green line represents patients 
with a CHA2DS2-VASc score of 4-5. The red line represents patients 
with a CHA2DS2-VASc score of 1-3. The blue line indicates patients 
without atrial fibrillation.
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Discussion
The principal findings of the present analysis can be summarised as 
follows: 1) a diagnosis of AF was documented in 5.3% of unselected 
patients undergoing PCI; 2) AF was associated with an increased risk 
of the primary composite endpoint of all-cause mortality, non-fatal 
MI, ischaemic stroke, and types 3b, 3c, 5a, 5b BARC bleeding 
through four years; 3) AF was also associated with an increased risk 
of the individual endpoints of all-cause mortality, ischaemic stroke, 
and intracranial bleeding; 4) the increased risk was directly related to 
increasing CHA2DS2-VASc scores; 5) AF in combination with renal 
failure portended a particularly poor long-term outcome.  
The prevalence of AF in this unselected patient population under-
going PCI with the unrestricted use of DES amounted to 5.3%, 
which is consistent with previous reports of patients with stable 
CAD and acute MI2-7. In line with established risk factors for AF8,9, 
patients with AF were older and had a higher prevalence of hyper-
tension and compromised left ventricular ejection fraction. Of note, 
only a minority of patients were treated with triple antiplatelet ther-
apy, while most patients were discharged on DAPT.
Patients with AF had a higher risk of the primary composite out-
come as well as the individual endpoints including all-cause mor-
tality, ischaemic stroke, and intracranial bleeding compared to 
patients without AF, whereas there were no differences in terms of 
non-fatal MI, ST, or repeat revascularisation procedures. Landmark 
analyses for the primary composite endpoint as well as all-cause 
mortality demonstrated a steady risk during the entire duration of 
follow-up with no differences between the first year and subsequent 
years. The association of AF with all-cause mortality corroborated 
the findings of previous studies8-10,14, persisted even after full adjust-
ment of baseline characteristics, and was not accompanied by dif-
ferences in the incidence of non-fatal MI or ST, suggesting a 
potential relationship with the occurrence of ischaemic and haem-
orrhagic strokes. The CHA2DS2-VASc score directly correlated 
with the risk of the primary composite endpoint.
We observed a particularly increased risk of adverse outcome among 
patients with new-onset AF. This observation is in line with a commu-
nity-based study, which showed an excess mortality within the first 
four months after newly diagnosed AF (HR 9.62, 95% CI 8.93-10.32) 
as compared to beyond the first four months (HR 1.66, 95% CI 1.59-
1.73). Similarly, patients with acute MI complicated by AF were found 
to have an increased risk of all-cause mortality (HR 1.82, 95% CI 1.39-
2.39, p<0.001) and stroke (HR 2.29, 95% CI 1.43-3.68, p<0.001) up to 
three years of follow-up in the OPTIMAAL experience10.
Patients with AF were at increased risk of both ischaemic stroke 
and intracranial bleeding. In addition, a trend towards a higher inci-
dence of BARC bleeding type 3a was observed in patients with AF. 
Oral anticoagulation was installed at discharge in 19% of patients 
- in a majority of patients in combination with DAPT - whereas a 
recommendation to recommence oral anticoagulation within three 
months of DES implantation (after discontinuation of either aspirin 
or clopidogrel) was made in another 22% of patients. Treatment 
recommendations from the ESC Working Group on Thrombosis 
support uninterrupted VKA treatment as an alternative to heparin 
bridging therapy in the periprocedural phase, endorse triple therapy 
post-interventionally instead of temporary replacement of VKA by 
dual antiplatelet drug therapy, and recommend the avoidance of 
DES in patients with very high bleeding risk14. A North American 
consensus document recommends a radial access in order to reduce 
periprocedural bleeding, generally prefers BMS over DES, and 
suggests considering proton pump inhibitors (e.g., pantoprazole) 
for patients with triple therapy15. Antithrombotic strategies follow-
ing coronary artery stenting differ between European and North 
American consensus documents. In elective cases, European 
experts recommend triple therapy for the duration of three months 
for patients treated with limus analogues and six months for patients 
treated with paclitaxel-eluting stents, and for the duration of six 
months in patients undergoing PCI for acute coronary syndromes 
irrespective of the stent. In contrast, North American guidelines 
recommend triple therapy for at least six months in patients with 
low risk of stent thrombosis and bleeding, and for 12 months in 
patients with high risk of stent thrombosis and low risk of bleeding. 
Both consensus documents were published after recruitment of our 
study population and did not reflect the standard of care at our insti-
tution during the inclusion phase of our registry.
In the largest randomised trial to date comparing 573 patients 
undergoing PCI, patients receiving dual therapy with oral antico-
agulants and clopidogrel were found to have significantly fewer 
TIMI bleeding events compared with patients receiving  triple ther-
apy including aspirin, whereas numbers of stent thrombosis, myo-
cardial infarction, and stroke were comparable (Dewilde W, What is 
the Optimal Antiplatelet and Anticoagulant Therapy in Patients 
with Oral Anticoagulation and Coronary Stenting (WOEST) trial. 
Oral presentation, ESC, Munich 2012). Among AF patients fol-
lowed in a large integrated healthcare system in Northern California, 
oral anticoagulation reduced the risk of ischaemic stroke and all-
cause mortality, while increasing the risk of intracranial haemor-
rhage as compared to patients without oral anticoagulation26. 
Patients with both a diagnosis of CAD requiring revascularisation 
by PCI as well as AF represent a high-risk population at either side 
of the risk scale (ischaemia and bleeding). Thus, the presence of 
CAD has been associated with a strong trend towards an increased 
risk of thromboembolic events21 among patients with AF. At the 
same time, triple antithrombotic therapy in patients undergoing PCI 
with AF has been associated with a higher incidence of major 
bleeding events compared with other regimens27. Of note, risk 
scores for bleeding or stroke cannot be easily generalised to patients 
with AF undergoing PCI with DES as they do not take into consid-
eration the risk of stent thrombosis21,28 and the duration of antithrom-
botic therapy. However, we did not observe a difference in the 
incidence of ST between patients with and without AF in the pre-
sent study. Although we can only speculate how event rates in terms 
of ischaemic risk reduction and bleeding risk increase would have 
been with a more aggressive regimen of triple antithrombotic ther-
apy, the adverse outcome of patients with AF undergoing PCI with 
DES requires more research as to the optimal intensity and duration 
of antithrombotic therapy.
n   
1070
EuroIntervention 2
0
1
3
;8
:1061-1071 
In a stratified analysis of the primary composite outcome, we 
observed an excessive risk for patients with both AF and renal failure, 
corroborating the results of previous reports showing an increased 
risk of ischaemic stroke and all-cause mortality in such patients29,30. 
The increased thromboembolic risk among patients with AF and 
renal failure may be related to elevations in inflammatory markers 
and a procoagulant milieu31. Moreover, renal failure has been identi-
fied as an independent predictor of major haemorrhage in a cohort of 
outpatients treated with oral anticoagulants32, potentially related to 
platelet dysfunction in patients with renal failure33,34.
Limitations
This study has several limitations. Among patients with AF, differ-
ent antithrombotic regimens were applied according to the discre-
tion of the treating physician, not following a prospectively defined 
regimen; even though the recommended antithrombotic regimen at 
discharge and during follow-up was recorded, information in terms 
of the intensity of anticoagulation and compliance was not availa-
ble. However, patients taking oral anticoagulation for indications 
other than AF were excluded from the present study cohort. The 
current study reports on antithrombotic strategies including the use 
of aspirin, clopidogrel and VKA. The impact on outcome of combi-
nations with recently introduced antiplatelet agents such as prasug-
rel and ticagrelor, as well as with novel antithrombotic agents such 
as dabigatran, rivaroxaban, and apixaban, are not reflected by the 
present analysis. Bleeding data were recorded as evidenced by sig-
nificant changes in haemoglobin values, adverse events leading to 
hospitalisation and patient self-reported episodes. Due to recollec-
tion bias, minor bleeding events may have been underreported as 
compared with major bleeding events. We cannot differentiate 
whether atrial fibrillation is a risk marker or a risk factor although 
we adjusted for known risk factors associated with atrial fibrilla-
tion. In order to address this issue we looked into patients with new-
onset atrial fibrillation and observed an increased risk, suggesting 
that atrial fibrillation is a risk factor for adverse outcome rather than 
a marker.
Conclusions
Among patients with CAD undergoing revascularisation with the 
unrestricted use of DES, AF confers an increased risk of all-cause 
mortality, ischaemic stroke, and intracranial bleeding. The risk 
increase correlates with the CHA2DS2-VASc score. The current 
study provides the basis for future research investigating optimal 
intensity and duration of antithrombotic treatment among patients 
with CAD and AF.
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